Skip to main content

Table 1 Patients, disease and treatment characteristics

From: Efficacy of bevacizumab and chemotherapy in the first-line treatment of metastatic colorectal cancer: broadening KRAS-focused clinical view

  WT KRAS (n = 964) KRAS mutation (n = 658) p-value
Male, n (%) 593 (61.5) 405 (61.6) 0.999
Age at bevacizumab treatment initiation, median, (min-max) 61 yrs (22–85) 63 yrs (22–83) <0.001
Site of primary tumor, n (%)
 Colon 593 (61.5) 398 (60.5) 0.679
 Rectum 371 (38.5) 260 (39.5)  
PS at 1st line treatment initiation*, n (%)
 PS 0 378 (52.2) 264 (51.5) 0.811
 PS 1 333 (46.0) 242 (47.2)  
 PS 2 or PS 3 13 (1.8) 7 (1.4)  
Adjuvant chemotherapy**, n (%) 317 (32.9) 189 (28.7) 0.081
Resectability of metastases*
 Unresectable 543 (76.5) 374 (75.7) 0.695
 Potentially resectable 127 (17.9) 96 (19.4)  
 Resectable 40 (5.6) 24 (4.9)  
Sites of metastases at the time of the initiation of fist-line treatment*, n (%)
 Liver 518 (67.7) 350 (64.0) 0.174
 Lymph nodes 235 (30.7) 143 (26.1) 0.073
 Lungs 182 (23.8) 175 (32.0) 0.001
 Peritoneum 137 (17.9) 111 (20.3) 0.284
 Other localization 116 (15.2) 78 (14.3) 0.693
 2 and more metastasis 338 (44.2) 238 (43.5) 0.822
Bevacizumab regimen in first-line treatment, n (%)
 5 mg/kg every 2 weeks 613 (63.6) 436 (66.3) 0.290
 7.5 mg/kg every 3 weeks 351 (36.4) 222 (33.7)  
CT at first-line treatment initiation, n (%)
 FOLFOX 511 (53.0) 366 (55.6) 0.259
 XELOX 295 (30.6) 184 (28.0)  
 FOLFIRI 107 (11.1) 83 (12.6)  
 XELIRI 51 (5.3) 25 (3.8)  
Reason for first-line therapy termination, n (%)
 Disease progression 534 (64.7) 342 (63.0) 0.162
 Surgery 52 (6.3) 47 (8.7)  
 Adverse event of bevacizumab 48 (5.8) 24 (4.4)  
 Adverse event of chemotherapy 18 (2.2) 17 (3.1)  
 Other reason*** 173 (17.9) 113 (20.8)  
Subsequent anti-EGFR-based treatment, n (%)****
 In second line 342 (35.5) 15 (2.3) -
 In third line 245 (25.4) 8 (1.2)  
 In fourth line 21 (2.2) 3 (0.5)  
  1. M, presence of distant metastasis; PS, performance status; *PS data were available for 75% of patients in the wtKRAS subgroup and for 78% patients in the mutant KRAS subgroup. Data on metastasis sites at first-line treatment initiation was available in 79% and 83% of patients, respectively. Data on metastases resectability were available for 74% and 75% patients, respectively. **Adjuvant regimens included FUFA biweekly infusional 5-FU/LV, FOLFOX, capecitabine, and not specified adjuvant CT. ***Other reason for first-line therapy termination included lack of data availability, CR, patient refusal, and death. ****The regimen with anti-EGFR antibodies were following: FOLFOX4+ panitumumab, FOLFIRI + panitumumab, FOLFOX4 + cetuximab, FOLFIRI + cetuximab, irinotecan (250 mg/m2 IV every 2 weeks) + cetuximab, panitumumab or cetuximab as single agents. Schedules and dosage of chemotherapy was identical to those applied in the first-line treatment. Panitumumab was administered 6 mg/kg IV every 2 weeks, cetuximab was administered 500 mg/m2 IV every 2 weeks or 400 mg/m2 IV first infusion, then 250 mg/m2 IV weekly. The registry did not provide reliable data on number of patients treated subsequently with chemotherapy alone. The chemotherapeutic regimen applied without addition of anti-EGFR antibodies were FOLFOX, FOLFIRI, XELOX or XELIRI as defined in Methods section.